 |
|
|
| |
Low Frequency of Anemia in Phase 3 Trials of ABT-450/r/ABT-267 and ABT-333 With Ribavirin in Treatment-naïve (SAPPHIRE-I) and Treatment-experienced (SAPPHIRE-II) Patients
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference, 20-25 July, 2014, Melbourne, Australia
Mark S Sulkowski1, David R Nelson2, Heiner Wedemeyer3, Fred Poordad4, Gregory T Everson5, Stuart K Roberts6, Darrell Crawford7, Graham R Foster8, Ira M Jacobson9, Geoff rey Dusheiko10, Barbara McGovern11, Junyuan Xiong11, Eoin Coakley11, Tolga Baykal11, Jordan J Feld12
1Johns Hopkins University, Balti more, Maryland, United States; 2University of Florida College of Medicine, Gainesville, Florida, United States; 3Medizinische Hochschule Hannover, Hannover, Germany; 4The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States;
5University of Colorado Denver, Aurora, Colorado, United States; 6The Alfred Hospital, Melbourne, Australia; 7Gallipoli Medical Research Foundation and School of Medicine, The University of Queensland, Brisbane, Australia; 8Queen Marys University of London, Barts Health, London, United Kingdom;
9Weill Cornell Medical College, New York, New York, United States; 10The Royal Free Hospital, London, United Kingdom; 11AbbVie Inc., North Chicago, Illinois, United States; 12Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada.
|
| |
|
|
|
|
|
